DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
CONCLUSIONS: This modelling study suggests that earlier initiation of LAMA/LABA or triple therapy may have positive benefits in slowing disease progression in patients with COPD. Greater benefits were demonstrated with early initiation therapy with triple versus LAMA/LABA.PMID:37382864 | DOI:10.1007/s12325-023-02583-1 (Source: Adv Data)
Source: Adv Data - June 29, 2023 Category: Epidemiology Authors: Dave Singh Diego Litewka Rafael P áramo Adrian Rendon Abdullah Sayiner Suzana E Tanni Sudeep Acharya Bhumika Aggarwal Afisi S Ismaila Raj Sharma Peter Daley-Yates Source Type: research
Clinic versus home spirometry for monitoring lung function in patients with asthma
Chest. 2023 Jun 27:S0012-3692(23)00935-2. doi: 10.1016/j.chest.2023.06.029. Online ahead of print.ABSTRACTBACKGROUND: Studies examining agreement between home and clinic spirometry in patients with asthma are limited, with conflicting results. Understanding the strengths and limitations of telehealth and home spirometry is particularly important considering the SARS-CoV-2 pandemic.RESEARCH QUESTION: How well do home and clinic measurements of trough forced expiratory volume in 1 second (FEV1) agree in patients with uncontrolled asthma?STUDY DESIGN AND METHODS: This post hoc analysis used trough FEV1 data from the randomise...
Source: Chest - June 29, 2023 Category: Respiratory Medicine Authors: John Oppenheimer Nicola A Hanania Rekha Chaudhuri Hironori Sagara Zelie Bailes Andrew Fowler Guy Peachey Emilio Pizzichini David Slade Source Type: research
Experimental drugs in clinical trials for COPD: Artificial Intelligence via Machine Learning approach to predict the successful advance from early-stage development to approval
Expert Opin Investig Drugs. 2023 Jun 26. doi: 10.1080/13543784.2023.2230138. Online ahead of print.ABSTRACTINTRODUCTION: Therapeutic advances in drug therapy of chronic obstructive pulmonary disease (COPD) really effective in suppressing the pathological processes underlying the disease deterioration are still needed. Artificial Intelligence (AI) via Machine Learning (ML) may represent an effective tool to predict clinical development of investigational agents.AREAL COVERED: Experimental drugs in Phase I and II development for COPD from early 2014 to late 2022 were identified in the ClinicalTrials.gov database. Different M...
Source: Expert Opinion on Investigational Drugs - June 26, 2023 Category: Drugs & Pharmacology Authors: Luigino Calzetta Elena Pistocchini Alfredo Chetta Paola Rogliani Mario Cazzola Source Type: research
A large particle size is required by a nano/micron sized-fluticasone propionate inhalable suspension for asthma treatment
This study showed that the particle size of FPs had a significant impact on their absorption, elimination and cellular distribution in the lung after inhalation and further on their effectiveness in asthma treatment, and the particle size of the nano/micron sized-FPs should be designed and optimized for asthma treatment on the premise of meeting the requirements of inhalation preparations.PMID:37290201 | DOI:10.1016/j.colsurfb.2023.113364 (Source: Colloids and Surfaces)
Source: Colloids and Surfaces - June 8, 2023 Category: Biotechnology Authors: Mi Zhang Su Jia Si Wen Jin Dai Jian Yang Yan Wang Xiang Rong Wei Shuo Liu Cheng Yi Xu Cong Zhang Fang Jin Li Qun Jiang Source Type: research
A large particle size is required by a nano/micron sized-fluticasone propionate inhalable suspension for asthma treatment
This study showed that the particle size of FPs had a significant impact on their absorption, elimination and cellular distribution in the lung after inhalation and further on their effectiveness in asthma treatment, and the particle size of the nano/micron sized-FPs should be designed and optimized for asthma treatment on the premise of meeting the requirements of inhalation preparations.PMID:37290201 | DOI:10.1016/j.colsurfb.2023.113364 (Source: Colloids and Surfaces)
Source: Colloids and Surfaces - June 8, 2023 Category: Biotechnology Authors: Mi Zhang Su Jia Si Wen Jin Dai Jian Yang Yan Wang Xiang Rong Wei Shuo Liu Cheng Yi Xu Cong Zhang Fang Jin Li Qun Jiang Source Type: research
Comparative efficacy and acceptability of licensed dose intranasal corticosteroids for moderate-to-severe allergic rhinitis: a systematic review and network meta-analysis
No evidence shows that one intranasal corticosteroid (INCS) is better than another for treating moderate-to-severe allergic rhinitis (AR). This network meta-analysis assessed the comparative efficacy and acceptability of licensed dose aqueous INCSs. PubMed/MEDLINE, Scopus, EMBASE, and the Cochrane Central Register of Controlled Trials were searched until 31 March 2022. Eligible studies included randomized controlled trials comparing INCSs with placebo or other types of INCSs in patients with moderate-to-severe allergic rhinitis. Two reviewers independently screened and extracted data following the Preferred Reporting Items...
Source: Frontiers in Pharmacology - May 23, 2023 Category: Drugs & Pharmacology Source Type: research
Fluticasone Propionate with Azelastine Versus Standalone Fluticasone Propionate as Nasal Spray in Allergic Rhinitis: A Prospective Comparative Study in a Rural Population of Northern India
Conclusions: According to results obtained from the current study, while both fluticasone propionate with azelastine nasal spray and standalone fluticasone propionate nasal spray are widely used for control of symptoms in PER, the former offers better results with significant reduction of symptoms when compared to the latter. (Source: Indian Journal of Otolaryngology and Head and Neck Surgery)
Source: Indian Journal of Otolaryngology and Head and Neck Surgery - May 6, 2023 Category: ENT & OMF Source Type: research
The Rising Cost of Rhinologic Medications
CONCLUSION: The rising cost of highly utilized medications contribute to increased patient acquisition costs and may pose barriers of drug adherence to particularly vulnerable populations.PMID:37098404 | DOI:10.1016/j.anai.2023.04.013 (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - April 25, 2023 Category: Allergy & Immunology Authors: Milind Vasudev Sina J Torabi Lauren Michelle Leo L T Meller Jack L Birkenbeuel Kelsey M Roman Theodore V Nguyen Edward C Kuan Source Type: research
The Rising Cost of Rhinologic Medications
CONCLUSION: The rising cost of highly utilized medications contribute to increased patient acquisition costs and may pose barriers of drug adherence to particularly vulnerable populations.PMID:37098404 | DOI:10.1016/j.anai.2023.04.013 (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - April 25, 2023 Category: Allergy & Immunology Authors: Milind Vasudev Sina J Torabi Lauren Michelle Leo L T Meller Jack L Birkenbeuel Kelsey M Roman Theodore V Nguyen Edward C Kuan Source Type: research
Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan
Conclusion: Once-daily FF/UMEC/VI 200/62.5/25 μg was effective against asthma without serious adverse events. This is the first report that demonstrated FF/UMEC/VI dilated peripheral airways using lung function tests. This evidence on drug effects may improve our understanding of pulmonary physiology and the pathophysiology of asthma. (Source: Frontiers in Physiology)
Source: Frontiers in Physiology - April 21, 2023 Category: Physiology Source Type: research
Central and peripheral lung deposition of fluticasone propionate dry powder inhaler formulations in humans characterized by population pharmacokinetics
This study aimed to gain an in-depth understanding of the pulmonary fate of three experimental fluticasone propionate (FP) dry powder inhaler formulations which differed in mass median aerodynamic diameters (MMAD; A-4.5 µm, B-3.8 µm and C-3.7 µm; total single dose: 500 µg). Systemic disposition parameter estimates were obtained from published pharmacokinetic data after intravenous dosing to improve robustness. A biphasic pulmonary absorption model, with mucociliary clearance from the slower absorption comp artment, and three systemic disposition compartments was most suitable. Rapid absorption, presumably from per...
Source: Pharmaceutical Research - April 20, 2023 Category: Drugs & Pharmacology Source Type: research
Tezepelumab treatment for allergic bronchopulmonary aspergillosis
The patient with allergic bronchopulmonary aspergillosis (ABPA) underwent treatment with tezepelumab; the mucus plugs and pulmonary opacities diminished gradually parallel to the improvement in the control of asthmatic symptoms. Tezepelumab might provide a novel steroid-sparing strategy for the management of ABPA. AbstractAn 82-year-old man had been diagnosed with asthma. He experienced repeated exacerbations requiring treatment with a systemic corticosteroid despite being treated with medications including high-dose fluticasone furoate/umeclidinium/vilanterol, montelukast sodium, and theophylline; treatment with mepolizum...
Source: Respirology Case Reports - April 18, 2023 Category: Respiratory Medicine Authors: Hiroaki Ogata,
Kachi Sha,
Yasuaki Kotetsu,
Aimi Enokizu ‐Ogawa,
Katsuyuki Katahira,
Akiko Ishimatsu,
Kazuhito Taguchi,
Atsushi Moriwaki,
Makoto Yoshida Tags: CASE REPORT Source Type: research
Drug-induced tooth discoloration: An analysis of the US food and drug administration adverse event reporting system
Conclusion: This study revealed that certain drugs are significantly associated with tooth discoloration. Caution should be exercised when using these drugs, especially during pregnancy and early childhood. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - April 13, 2023 Category: Drugs & Pharmacology Source Type: research
